FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.
What happened
FDA inspected Eurosirel’s drug manufacturing facility in Cusago, Milan, from May 20 to 24, 2024. The agency found the company did not test each component lot for identity and relied on supplier certificates of analysis without verifying them; glycerin used in pain patches lacked USP identity testing for DEG/EG. FDA also found the quality unit failed to ensure equipment cleaning/maintenance records and complete batch records.
What FDA found
Eurosirel did not conduct at least one identity test for each component lot used in its drug products.
21 CFR 211.84(d)(1)Eurosirel relied on supplier certificates of analysis without validating and establishing the reliability of supplier test analyses at appropriate intervals.
21 CFR 211.84(d)(2)Eurosirel did not test each shipment and lot of glycerin for identity, including the USP limit test for DEG and EG, even though glycerin is used in its pain patches.
21 CFR 211.84(d)(1) and (2)Eurosirel’s quality unit failed to ensure written records of major equipment cleaning, maintenance, and use.
21 CFR 211.22(a); 21 CFR 211.182Eurosirel’s quality unit failed to ensure complete batch and control records for each batch of drug product.
21 CFR 211.22(a); 21 CFR 211.188
What FDA wants
FDA asks Eurosirel to correct the violations promptly and respond in writing within 15 working days, explaining corrective actions and how it will prevent recurrence. If it cannot complete actions within that time, it must state the reasons for delay and a completion schedule.
Who should pay attention
- brands that buy topical drugs or pain patches from this contract manufacturer
- US importers and distributors of Eurosirel products
- drugmakers that rely on supplier certificates of analysis for high-risk components such as glycerin
This is a summary. Read the original letter on fda.gov.